

Synthesis and Antitumor Activity of 4 β -(1,2,3-Triazol-1-yl) podophyllotoxins

Chang Nian CAO², Yu Yin CHEN¹, Yan Guang WANG^{1*}, Yao Zu CHEN¹


¹Department of Chemistry, Zhejiang University, Hangzhou 310027;

²Department of Applied Chemistry, Qinghai University, Xining 810000


Abstract: Three 4 β -(1,2,3-triazol-1-yl) podophyllotoxins **2–4** have been synthesized and tested for their antitumor activity *in vitro*. The compound **3** was found to be much more cytotoxic than the clinically used etoposide (VP-16) against L1210 cells.

Keywords: Podophyllotoxin, antitumor, synthesis.

Semisynthetic analogues of the naturally occurring podophyllotoxin **1** have renewed interest in recent years as a result of the development of etoposide (VP-16) as anticancer drug^{1–6}. In previous studies^{7–13}, we found that a number of 4 β -amino- or amido-podophyllotoxins were as active or more active than VP-16. Here, we report the synthesis and *in vitro* antitumor activity of three 4 β -(1,2,3-triazol-1-yl) podophyllotoxins with structural features shown in formulae **2–4**.




1



2 R= R' = Me

3 R=Me, R' = -C₆H₅

4 R=H, R' = Me

Scheme 1. Synthesis of 4 β -(1,2,3-triazol-1-yl)podophyllotoxins**Table 1.** Physical Properties and Analytic Data of Compounds 2~4

Compound*	Yield (%)	m.p. (°C)	IR(KBr) (cm ⁻¹)	MS(EI,70eV) m/z
2	63	141-143	1778 (lactone), 1585, 1505 and 1482 (aromatic C=C)	479 (M ⁺ ,54), 397 (24) 196 (65), 381 (10)
3	52	232-235	1780 (lactone), 1585, 1505 and 1485 (aromatic C=C)	541 (M ⁺ ,39), 495 (5) 397 (32), 396 (100)
4	42	160-162	1762(lactone), 1580, 1510 and 1480 (aromatic C=C)	465 (M ⁺ ,23), 383 (34) 382(100), 369(4)

* The microanalyses were in satisfactory agreement with the calculated values (C, H and N) within $\pm 0.27\%$.

The 4 β -(1,2,3-triazol-1-yl)podophyllotoxins **2~4** were synthesized as shown in **Scheme 1**. A mixture of podophyllotoxin **1** and HN₃ in CH₂Cl₂ was treated with a solution of BF₃·OEt₂ in CH₂Cl₂ to give 4 β -azidopodophyllotoxin **5**. The bulky C-1 α pendant aromatic ring dictates the reaction to be stereoselective in yielding the 4 β -azido isomer as the major products. The ratio between 4 β -azidopodophyllotoxin **5** and its 4 α -isomer was about 15:1 according to TLC analysis. The assignment of the configuration at C-4 for compound **5** was based on the difference of J_{3,4} coupling constants. The 4 β -substituted podophyllotoxins have a J_{3,4} \approx 4.5Hz, due to a *cis* relationship between H-3 and H-4^{14,15}. The 4 α -substituted isomers, however, have a J_{3,4}

≥ 10.0 Hz as H-3 is *trans* to H-4^{14,15}.

The 4 β -azido-4'-O-demethylpodophyllotoxin 6 was obtained from 1 in three steps by our previous method⁷⁻¹³. The 1,3-dipolar cycloaddition of azides 5 and 6 with the corresponding alkylidene phosphoranes 7 in anhydrous benzene under reflux resulted in 1,2,3-triazoles 2, 3 and 4, respectively.

All new compounds were characterized by m.p., IR, ¹H NMR and MS spectra as well as elemental analysis as shown in **Table 1** and **2**.

Table 3. ¹H NMR Data of Compounds **2-4**

Compound	δ (ppm)
2	7.517 (s, 1H), 6.611 (s, 1H), 6.411 (s, 1H), 6.352 (s, 2H), 5.943 (dd, 2H), 5.683 (d, J = 5.4 Hz, 1H), 4.788 (d, J = 5.1 Hz, 1H), 4.208 (t, 1H), 3.942 (dd, 1H), 3.797 (s, 3H), 3.752 (s, 6H), 3.208 (m, 1H), 3.013 (dd, 1H), 2.365 (s, 3H).
3	7.771 (s, 1H), 7.590 and 7.375 (m, 5H), 6.603 (s, 1H), 6.417 (s, 1H), 6.311 (s, 2H), 5.942 (dd, J = 1.2, 15.0 Hz, 2H), 5.723 (d, J = 5.4 Hz, 1H), 4.788 (d, J = 5.1 Hz, 1H), 4.184-4.095 (m, 2H), 3.772 (s, 3H), 3.723 (s, 6H), 3.194-3.051 (m, 2H).
4	7.52 (s, 1H), 6.62 (s, 1H), 6.42 (s, 1H), 6.37 (s, 2H), 5.94 (brs, 2H), 5.68 (d, J = 5.4 Hz, 1H), 5.46 (s, 1H), 4.79 (d, J = 5.1 Hz, 1H), 4.22 (t, 1H), 3.92 (d, 1H), 3.78 (s, 6H), 3.37 (s, 3H), 3.21-3.01 (m, 2H).

The *in vitro* cytotoxicity test was carried out in L1210 cells. **2** (ID₅₀ = 0.13 μ M) and **4** (ID₅₀ = 0.17 μ M) exhibited almost equivalent activity to VP-16 (ID₅₀ = 0.15 μ M), whereas **3** (ID₅₀ = 0.0030 μ M) was 50-fold more cytotoxic than VP-16 against L1210 cells. Further biological evaluation of synthesized compounds is in progress, and the results will be reported elsewhere.

References

- P. J. O'Dwyer, B. Leyland-Jones, M. T. Alonso, S. Marsoni, R. E. Wittes, *N. Engl. J. Med.*, **1985**, *312*, 692.
- K. H. Lee, "Antineoplastic Agents for Chinese Traditional Medicine and their Analogs. I *Human Medicinal Agents from Plants*," American Chemical Society, Symposium Series, A. D. Kinghorn and M. Balandrin, Eds., American Chemical Society, Washington, DC, **1993**, pp. 170.
- Y. L. Zhang, A. Tropsha, A. T. McPhail, K. H. Lee, *J. Med. Chem.*, **1994**, *37*, 1460.
- X. M. Zhou, K. J. H. Lee, J. Cheng, S. S. Wu, H. X. Chen, X. Guo, Y. C. Cheng, K. H. Lee, *J. Med. Chem.*, **1994**, *37*, 287.
- A. Kamal, N. L. Gayatri, *Tetrahedron Lett.*, **1996**, *37*, 3359.
- L. Daley, P. Meresse, E. Bertouesque, C. Monneret, *Tetrahedron Lett.*, **1997**, *38*, 2673.
- X. Tian, Y. G. Wang, M. G. Yang, Y. Z. Chen, *Life Sci.*, **1997**, *60*, 511.
- J. L. Pan, Y. G. Wang, Y. Z. Chen, *Current Sci.*, **1997**, *72*, 268.

9. Y. G. Wang, L. Tao, J. L. Pan, J. F. Shi, Y. Z. Chen, *Chem. J. Chin. Univ.*, **1997**, *18*, 1061.
10. Y. Z. Chen, Y. G. Wang, J. X. Li, X. Tian, Z. P. Jia, P. Y. Zhang, *Life Sci.*, **1989**, *45*, 2569.
11. Y. G. Wang, J. L. Pan, J. F. Shi, Y. Z. Chen, *Life Sci.*, **1997**, *61*, 537.
12. K. K. Lu, Y. G. Wang, Y. Z. Chen, *Synthetic Commun.*, **1997**, *27*, 1963.
13. J. L. Pan, Y. G. Wang, Y. Z. Chen, *Acta Pharmaceutica Sinica*, **1997**, *32*, 898.
14. Y. L. Zhang, Y. C. Shen, Z. Q. Wang, H. X. Chen, X. Guo, Y. C. Cheng, H. K. Lee, *J. Nat. Prod.*, **1992**, *55*, 1100.
15. Z. Q. Wang, H. Hu, H. X. Cheng, Y. C. Cheng, K. H. Lee, *J. Med. Chem.*, **1992**, *35*, 871.
16. L. Jacques, W. Claude, *Synth. Commun.*, **1984**, *37*, 496.

Received 29 June 1999